Hematolojik Endokrinoloji

Yıl 2006, Cilt: 4 Sayı: 1, 133 - 136, 01.04.2006

Ömer Tarım

Öz

Kanın birincil işlevleri doku oksijenizasyonu, immün savunma ve hemostazın sağlanmasıdır. Bu görevini yerine getirmesi için, kemik iliğinin çok sıkı bir kontrol altında, günde 1011 olgun hücre üretmesi gerekir. Sitokinler denilen hemopoetik düzenleyici proteinler, bu kontrolün sağlanmasına, endokrin, parakrin ve otokrin mekanizmalarla yardımcı olur 1 .

Kaynakça

• 1. Luksenburg HS, Goldberg SL, Kessler CM. Hematologic endocrinology. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism Philadelphia: Lippincott Williams & Wilkins 2001: 1927-37.
• 2. Saka NS, Tütüncüler F. Çocukluk çağı kronik hematolojik ve onkolojik hastalıklarında endokrin patolojiler. Türkiye Klinikleri J Pediatr Özel, 2004/447-455
• 3. Baum CM, Uchida N, Peault B, Weissman IL. Isolation and characterization of hematopoetic progenitor and stem cells. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Cambridge MA: Blackwell Science, 1994: 53-67.
• 4. Krantz SB. Erythropoietin. Blood 1991; 77:419-34.
• 5. Schreiber S, Howaldt S, Schnoor MS, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619-23.
• 6. Sieff CA, Emerson SG, Donahue RE, et al. Human recombinant granulocyte- macrophage colony stimulating factor: a multilineage hematopoietin. Science 1985; 230:1171-3.
• 7. Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 1998; 35:261-8.
• 8. Maslak P, Nimer S. The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. Semin Hematol 1998; 35:253-60.
• 9. Ten Have SM, van der Lely AJ, Lamberts SW. Increase in haemoglobin concentration in growth hormone concentration in growth hormone deficient adults during human recombinant growth hormone replacement therapy. Clin Endocrinol (Oxf) 1997; 47:565-70.
• 10. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90:2515-21.
• 11. Kuhn JM, Rieu M, Rochette J, et al. Influence of thyroid status on hemoglobin A2 expression. J Clin Endocrinol Metab 1983; 57:344-8.
• 12. Ansell JE. The blood in hypothyroidism. In: Braverman LE, Utiger RD, eds. The thyroid: a fundamental and clinical text. Philadelphia: JB Lippincott Co, 1991:1022-114.
• 13. Hofbauer LC, Spitzweg C, Schmauss S, et al. Graves disease associated with autoimmune thrombocytopenic purpura. Arch Intern Med 1997; 157:1033-6.
• 14. Myrup B, Bregengard C, Faber J. Primary hemostasis in thyroid disease. J Intern Med 1995; 238:59-63.
• 15. Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism and anemia in renal failure. Am J Nephrol 2000; 20:89-96.
• 16. Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980-91.
• 17. Cotroneo P, Maria Ricerca B, Todaro L, et al. Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes Metab Res Rev 2000; 16:172-6.
• 18. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. JAMA 2000; 283: 221-8.
• 19. Besa EC. Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Semin Hematol 1994; 31:134-45.
• 20. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, et al. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Haemost Thromb 1997; 78: 327-33.
• 21. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453-7.
• 22. Broxmeyer HE, Lu L, Cooper S, et al. Selective and indirect modulation of human amultipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci USA 1988; 85:9052-6.